Thus, the rescue effects of SUCLG2 knockdown or α-KG/Gln supplementation confirmed the crucial role of SLC25A21 in repressing KRAS-mutant CRC progression by arresting α-KG efflux from mitochondria and thus promoting anaplerotic Gln flux into the TCA cycle. The gene discussed is KRAS; the disease is colorectal carcinoma.